WebEvofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products and product candidates to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Evofem’s sole purpose is to improve ... Web2 days ago · SAN DIEGO, April 12, 2024 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced a major new win in New York state that improves coverage for Phexxi® (lactic acid, citric acid ...
Evofem Wins Phexxi Coverage with Largest Payer in New York with …
WebAug 4, 2024 · Evofem continues to expect net product sales in the range of $30 to $35 million for its 2024 fiscal year, representing 264% to 325% growth year-over-year. Gross … WebCurrently, Amy Raskopf holds the position of Head-Investor Relations at Evofem Biosciences, Inc. and Strategic Communications Specialist at In-Site Communications, Inc. Ms. Raskopf previously was ... bridge of scarlet leaves
Evofem Biosciences to Host Investor Call on Thursday, August 11 …
WebJul 28, 2024 · Evofem Biosciences to Report Second Quarter 2024 Results and Provide Corporate Update on Thursday, August 4, 2024 - read this article along with other … WebApr 14, 2024 · SAN DIEGO , April 14, 2024 /PRNewswire/ --Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2024.Reporting to Chief Executive Officer Saundra Pelletier, … WebAug 4, 2024 · Amy Raskopf, Evofem Biosciences’ Head of Investor Relations. Ma'am, please go ahead. Amy Raskopf Thank you, and good morning, everyone. Welcome to … bridge of san luis rey